Table 3.
Summary of Functional Outcomes After a Single Transurethral Ultrasound Ablation Procedure: Preservation of Potency and Continence, and Stability of Urinary Symptoms
| Study | Prior PCa treatment | FU at (months) | BL potency preserveda | BL continence preserved | Change in urinary symptoms | Definition for change in urinary symptoms |
|---|---|---|---|---|---|---|
| Klotz8 | None (115/115) | 12 | 75% (69/92) IIEF Q2 ≥ 2 |
92% (103/112) EPIC pad-free |
Δ = 14% BL: 7 (3–10) FU: 6 (3–9) |
Change in IPSS |
| Eggener9,b | 24 | 83.3% IIEF Q2 ≥ 2 |
93% EPIC pad-free |
Δ = 28% BL = 7 (3–10) FU = 5 |
||
| Lumiani10 | Primary PCa (47/52): None Recurrent PCa (5/52): 3/5 HIFUa 1/5 laser 1/5 EBRT 1/5 hyperthermia |
16 (12–22) Median (IQR) |
98% (40/41) 100% (4/4) Surgeon-assessed partial or full potency |
98% (46/47) 100% (5/5) Pad-free |
92% (47/52) | Proportion of men with no deterioration in urinary function (surgeon-assessed reduced nocturia, incomplete bladder emptying; discontinuation of either permanent catheterization or BPH medication) |
| 83% (20/24) | (PCa and LUTS subgroup, 24/52): Proportion of men with improvement in urinary function (surgeon-assessed reduced nocturia, incomplete bladder emptying; discontinuation of either permanent catheterization or BPH medication) |
|||||
| Chin11 | None (30/30) | 12 | 85% (17/20) IIEF Q2 ≥ 2 |
100% (30/30) EPIC leak-free and pad-free |
Δ = 38% BL = 8 (5–13) FU = 5 (4–7) |
Change in IPSS |
| Nair 202012 | 36 | BL = 13/22 FU = 11/22 IIEF Q2 ≥ 2 |
100% (22/22) EPIC leak-free and pad-free |
Δ = 0% BL = 6 (5–13) FU = 6 (4–10) |
Change in IPSS, for men continuing per-protocol FU at 3 years. | |
| Nair 2020b,13 | 60 | BL = 9/16 FU = 7/16 IIEF Q2 ≥ 2 |
100% (16/16) EPIC leak-free and pad-free |
Δ = 25% BL = 8 (5–13) FU = 6 (6–9) |
Change in IPSS, for men continuing per-protocol FU at 5 years. | |
| Elterman17 | 12 |
Δ = 7% BL = 15 ± 9 FU = 16 ± 9 IIEF-15 |
N/A |
Δ = 62% BL = 16 ± 4 FU = 6 ± 5 89% (8/9) |
Change in IPSS Proportion of men with decrease in IPSS ≥6 points from BL |
|
| Anttinen14 | None (6/6) | 3 weeks | 100% (3/3) IIEF Q2 ≥ 2 |
100 (6/6) EPIC urinary incontinence |
Δ = 20% BL = 5 (4–6) FU = 4 (3–8) |
Change in IPSS |
| Anttinen15 | 10/11 EBRT 1/11 HDR brachy 4/11 ADT |
12 | N/A (11/11 men had severe ED at BL) | BL = 100 (100–100) FU = 96 (46–100) EPIC urinary incontinence |
Δ = 12% BL = 8 (4–10) FU = 7 (5–18) |
Change in IPSS |
| Anttinen16 | 6/10 EBRT and 2–3-year ADT 4/10 ADT |
12 | N/A | N/A |
Δ = 100% (9/9) Δ = 100% (10/10) |
Freedom from gross hematuria (1/10 men free from gross hematuria at BL) Freedom from permanent catheterization (0/10 men free at BL) |
For the subgroups of men with cancer who also had benign prostatic hyperplasia at BL, improvement in urinary symptoms is also reported. Delta (Δ) is defined as the difference between BL and FU, normalized to BL and expressed as a percentage. Convention: a positive Δ denotes improvement. Median (IQR) is reported for IPSS and EPIC, and mean ± standard deviation for IIEF-15.
Erectile aid medications were allowed at BL and/or FU in all studies that evaluated erectile function.
Conference presentation.
BL = baseline; EPIC = Expanded Prostate Cancer Index; FU = follow-up; IIEF = International Index of Erectile Function; LUTS = lower urinary tract symptoms.